September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Superior efficacy of Lastacaft® versus Pataday in grass- and tree-allergic subjects
Author Affiliations & Notes
  • Stacey L Ackerman
    Ophthalmology, Philadelphia Eye Associates, Philadelphia, Pennsylvania, United States
  • Joseph B Ciolino
    Ophthalmology, MEEI, Harvard Medical School, Boston, Massachusetts, United States
  • Julia M Williams
    Global Medical Affairs, Allergan, Inc., Irvine, California, United States
  • David A Hollander
    Global Medical Affairs, Allergan, Inc., Irvine, California, United States
  • Footnotes
    Commercial Relationships   Stacey Ackerman, Allergan, Inc. (F); Joseph Ciolino, Ora, Inc. (C); Julia Williams, Allergan, Inc. (E); David Hollander, Allergan, Inc. (E)
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 312. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Stacey L Ackerman, Joseph B Ciolino, Julia M Williams, David A Hollander; Superior efficacy of Lastacaft® versus Pataday in grass- and tree-allergic subjects
      . Invest. Ophthalmol. Vis. Sci. 2016;57(12):312.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : Due to Lastacaft’s effect on epithelial tight junctions1, efficacy for ocular itching might be influenced by the type of allergen sensitivity. Our aim was to assess the onset of effect of Lastacaft versus Pataday administered 16 and 24 hours prior to exposure to allergen in subjects sensitized to grasses and trees and with a history of allergic conjunctivitis.

1Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Design, Development and Therapy. 2011;5:77-84.

Methods : Pooled data from two double-masked, multicenter studies using the conjunctival allergen challenge (CAC) model were analyzed in this post-hoc analysis. Subjects who qualified at baseline received one drop of Lastacaft® (0.25% alcaftadine) or Pataday® (olopatadine 0.2%) 16 hours and 24 hours prior to CAC. Itching was assessed after 3, 5, and 7 minutes. Mean differences, change from CAC-baseline, percent CAC-baseline itching, and percent responders with <1 itching were considered.

Results : A total of 111 subjects were treated with Lastacaft (48 grass-, 9 tree-sensitized) or Pataday (47 grass- and 7 tree-sensitized).

In grass-allergic subjects, 16 hours after dosing and 3 minutes post-CAC, Lastacaft was superior to Pataday with a mean difference of -0.42 (p=0.011). Change from baseline itching was -2.2 for Lastacaft versus -1.5 for Pataday (p=0.002); % baseline itching was -80.3% for Lastacaft and -60.2% for Pataday (p=0.005). Percent responders with scores <1 was also higher with Lastacaft (66.7%) than Pataday (47%), p=0.015.

In tree-allergic subjects, at 24 hours after dosing and 3 minutes post-CAC, Lastacaft showed the greatest change from baseline: -2.4 for Lastacaft versus -1.1 for Pataday (p=0.048). As % baseline itching, Lastacaft was -83.3% versus -41.4% for Pataday (p=0.045).

Conclusions : Lastacaft showed superior efficacy to Pataday for ocular itching at 16 and 24 hours in grass- and tree-allergic subjects at 3 minutes post-CAC. It has been hypothesized that Lastacaft offers epithelial barrier protection, which may explain the superior activity of Lastacaft compared to Pataday immediately after allergen exposure.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×